- Home
- ELEV vs DXST Comparison
ELEV vs DXST Comparison
Compare ELEV & DXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- DXST
- Stock Information
- Founded
- ELEV 2019
- DXST 2011
- Country
- ELEV United States
- DXST China
- Employees
- ELEV N/A
- DXST N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- DXST
- Sector
- ELEV Health Care
- DXST
- Exchange
- ELEV Nasdaq
- DXST NYSE
- Market Cap
- ELEV 18.1M
- DXST 18.7M
- IPO Year
- ELEV 2021
- DXST 2025
- Fundamental
- Price
- ELEV $0.32
- DXST $1.24
- Analyst Decision
- ELEV Buy
- DXST
- Analyst Count
- ELEV 6
- DXST 0
- Target Price
- ELEV $2.94
- DXST N/A
- AVG Volume (30 Days)
- ELEV 750.8K
- DXST 33.7K
- Earning Date
- ELEV 08-05-2025
- DXST 01-01-0001
- Dividend Yield
- ELEV N/A
- DXST N/A
- EPS Growth
- ELEV N/A
- DXST 13.11
- EPS
- ELEV N/A
- DXST 0.14
- Revenue
- ELEV N/A
- DXST $11,542,292.00
- Revenue This Year
- ELEV N/A
- DXST N/A
- Revenue Next Year
- ELEV N/A
- DXST N/A
- P/E Ratio
- ELEV N/A
- DXST $9.48
- Revenue Growth
- ELEV N/A
- DXST 22.18
- 52 Week Low
- ELEV $0.22
- DXST $0.85
- 52 Week High
- ELEV $3.77
- DXST $5.74
- Technical
- Relative Strength Index (RSI)
- ELEV 49.38
- DXST N/A
- Support Level
- ELEV $0.29
- DXST N/A
- Resistance Level
- ELEV $0.32
- DXST N/A
- Average True Range (ATR)
- ELEV 0.02
- DXST 0.00
- MACD
- ELEV 0.00
- DXST 0.00
- Stochastic Oscillator
- ELEV 59.01
- DXST 0.00
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.